Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Everolimus + Ribociclib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Everolimus||Afinitor||RAD001|Zortress||mTORC1 Inhibitor 9||Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, in adult and pediatric patients aged 1 year and older with tuberous sclerosis complex who have subependymal giant cell astrocytoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov).|
|Ribociclib||Kisqali||LEE011||CDK4/6 Inhibitor 10||Kisqali (ribociclib) is a dual CDK4/6 inhibitor, which may induce cell cycle arrest and reduce proliferation in cancer cells (PMID: 24045179). Kisqali (ribociclib) is FDA-approved in combination with an aromatase inhibitor in women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer, and in combination with Faslodex (fulvestrant) in postmenopausal women with hormone receptor-positive, ERBB2 (HER2)-negative breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||high grade glioma||not applicable||Everolimus + Ribociclib||Phase I||Actionable||In a Phase I trial, the combination treatment of Kisqali (ribociclib) and Afinitor (everolimus) did not result in any objective responses in pediatric patients with a malignant brain tumor (n=18) and led to 16 patients with disease progression, however, one patient had prolonged stable disease for 24 courses of treatment (PMID: 33547201; NCT03387020).||33547201|
|Unknown unknown||pancreatic adenocarcinoma||no benefit||Everolimus + Ribociclib||Phase I||Actionable||In a Phase I trial, treatment with the combination of Afinitor (everolimus) and Kisqali (ribociclib) did not lead to a clinical benefit in pancreatic adenocarcinoma patients who previously progressed on chemotherapy (n=11), resulting in a median progression-free survival of 1.8 months, a median overall survival of 3.7 months, stable disease in two patients for 8 weeks, and progressive disease in nine patients (PMID: 32642630; NCT02985125).||32642630|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03387020||Phase I||Ribociclib Everolimus + Ribociclib||Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors||Completed||USA||0|
|NCT03070301||Phase II||Everolimus + Ribociclib||A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors||Active, not recruiting||USA||0|
|NCT03834740||Phase I||Everolimus + Ribociclib||A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection||Recruiting||USA||0|
|NCT02985125||Phase Ib/II||Everolimus + Ribociclib||LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy||Active, not recruiting||USA||0|
|NCT03355794||Phase I||Everolimus + Ribociclib||A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)||Active, not recruiting||USA||0|
|NCT03114527||Phase II||Everolimus + Ribociclib||Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)||Recruiting||USA||0|